There are 1105 resources available
684P - A phase I study of a common neoantigen srRNA vaccine (JCXH-212) with or without toripalimab in patients with non-small cell lung cancer(NSCLC)
Presenter: Hanxiao Chen
Session: Poster Display session
Resources:
Abstract
685P - Genomic profiles in EGFR mutant locally advanced or metastatic NSCLC patients after first-line osimertinib treatment failure: A real-world, multi-center prospective study in China
Presenter: Yuan-Kai Shi
Session: Poster Display session
Resources:
Abstract
686P - The predictive efficacy of tumor mutational burden for Immune Checkpoint Inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials
Presenter: Min Ying
Session: Poster Display session
Resources:
Abstract
687P - Profile of actionable oncogenic alterations (AGA) among patients with advanced NSCLC in South India: A multicentric study
Presenter: Keechilat Pavithran
Session: Poster Display session
Resources:
Abstract
688P - The efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy for advanced KRAS-mutant non-small cell lung cancer
Presenter: Huiping Qiang
Session: Poster Display session
Resources:
Abstract
689P - Patterns of disease progression and efficacy of local ablative therapy among patients with metastatic EGFR-mutation positive non-small cell lung cancer treated with first-line osimertinib
Presenter: Chih Chi Chen
Session: Poster Display session
Resources:
Abstract
690P - Clinical outcomes of patients with advanced EGFR mutation positive (EGFRm) non-small cell lung cancer (NSCLC) with MET amplification (METamp) after osimertinib resistance: A multicentre retrospective study
Presenter: Olivia Han Chen
Session: Poster Display session
Resources:
Abstract
691P - Mechanisms of acquired resistance to first-line (1L) osimertinib in EGFR-mutated (EGFRm) advanced NSCLC: Results from a prospective, multi-center, real-world study in China (FLOURISH study)
Presenter: Jing Zheng
Session: Poster Display session
Resources:
Abstract
692P - Landscape of co-occurring OncoKB tier 1/2 alterations in EGFR-mutated lung adenocarcinoma (LUAD) harboring common driver alterations using circulating tumor DNA (ctDNA) next generation sequencing (NGS) in Asia and the Middle East (AME)
Presenter: Shaheenah Dawood
Session: Poster Display session
Resources:
Abstract
693P - Treatment comparison of amivantamab vs. real-world therapies among patients with NSCLC harboring EGFR Exon 20 insertion mutations: An external control analysis (ECA) using NTUH NSCLC dataset in Taiwan
Presenter: Jenn-Yu Wu
Session: Poster Display session
Resources:
Abstract